Lioness
21-12-08, 10:07 PM
Australian Hepatites B vaccine (HBV) schedule:
BIRTH - Monovalent hepatitis B vaccine
2 MONTHS - Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
4 MONTHS - Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
6 MONTHS- Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
12 MONTHS - Hepatitis B vaccine in combination with Hib (PRO-OMP), at 2, 4 and 12 months.
10-13 YEARS - Hepatitis B vaccine for 10-13 year olds who have not received a primary course
The Australian Immunisation Handbook http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-hepatitisb
Australian vaccination policy
The initial strategy for the control of hepatitis B in Australia commenced in 1988, targeting groups at particular risk of infection for vaccination at birth. In addition to vaccine, hepatitis B immunoglobulin (HBIG) was given if the mother was a hepatitis B carrier. In 1990, universal infant vaccination commenced in the Northern Territory. In 1996, the NHMRC recommended a universal hepatitis B vaccination program for infants and adolescents. The adolescent program commenced in some States and Territories in 1997 and the universal infant program, with the first dose given at birth, began nationally in 2000. The adolescent program will continue until those immunised for hepatitis B in the childhood program reach adolescence.
Recommendations
(i) Infants and young children
A birth dose of thiomersal-free monovalent hepatitis B vaccine, followed by doses given in combination vaccines (such as DTPa-hepB, DTPa-hepB-IPV,
DTPa-hepB-IPV-Hib or Hib (PRP-OMP)-hepB) at 2, 4 and either 6 or 12 months, is recommended for all children.
The rationale for the universal birth dose is not only to prevent vertical transmission from a carrier mother (recognising that there may be errors or delays in maternal testing, reporting, communication or appropriate response), but also to prevent horizontal transmission in the first months of life from a carrier among household or other close contacts.17 The birth dose should be given as soon as the baby is physiologically stable, and preferably within 24 hours of birth. Every effort should be made to administer the vaccine before discharge from the obstetric hospital.
Extensive experience indicates that the birth dose of hepatitis B vaccine is very well tolerated by newborn infants. It does not interfere with either the establishment or maintenance of breastfeeding, and it is not associated with an increased risk of either fever or medical investigation for sepsis in the newborn.18-20 (http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-hepatitisb#18)
If an infant has missed the birth dose and is aged 8 days or older, a catchup schedule is not required. A primary course of a hepatitis B-containing combination vaccine should be given at 2, 4 and either 6 or 12 months of age (provided the mother is HBsAg negative).
NB. All babies (preterm or term) of carrier mothers must be given a birth dose of hepatitis B vaccine and HBIG.
Vaccines
Engerix-B – GlaxoSmithKline (recombinant DNA hepatitis B vaccine).
Adult formulation – Each 1.0 mL monodose vial contains 20 μg recombinant hepatitis B surface antigen (HBsAg) protein, adsorbed onto 0.5 mg aluminium hydroxide. Paediatric formulation – Each 0.5 mL monodose vial contains 10 μg HBsAg protein, adsorbed onto 0.25 mg aluminium hydroxide. Both formulations contain traces of yeast proteins and thiomersal (<2 μg/mL). Both are available in packs of 10.
H-B-VAX II – CSL Biotherapies/Merck & Co Inc (recombinant DNA hepatitis B vaccine). Adult formulation preservative free – Each 1.0 mL pre-filled syringe or vial contains 10 μg recombinant HBsAg protein, adsorbed onto 0.5 mg aluminium hydroxide. May contain yeast proteins. Paediatric formulation preservative free – Each 0.5 mL pre-filled syringe or vial contains 5 μg recombinant HBsAg protein, adsorbed onto 0.25 mg aluminium hydroxide. May contain yeast proteins. Both are available in packs of 10. Dialysis formulation preservative free – Each 1.0 mL vial contains 40 μg recombinant HBsAg protein, adsorbed onto 0.5 mg aluminium hydroxide. May contain yeast proteins. Available as single pack only.
Combination vaccines that include both DTPa and hepatitis B
Infanrix hexa – GlaxoSmithKline (DTPa-hepB-IPV-Hib; diphtheriatetanus- acellular pertussis-hepatitis B-inactivated poliomyelitis vaccine-Haemophilus influenzae type b (Hib)). The vaccine consists of both a 0.5 mL pre-filled syringe containing 30 IU diphtheria toxoid, 40 IU tetanus toxoid, 25 μg pertussis toxoid (PT), 25 μg filamentous haemagglutinin (FHA), 8 μg pertactin (PRN), 10 μg recombinant HBsAg, 40 D-antigen units inactivated polioviruses type 1 (Mahoney), 8 D-antigen units type 2 (MEF-1) and 32 D-antigen units type 3 (Saukett) adsorbed onto aluminium hydroxide/phosphate; phenoxyethanol as preservative; traces of formaldehyde, polymyxin and neomycin and a vial containing a lyophilised pellet of 10 μg purified Hib capsular polysaccharide (PRP) conjugated to 20–40 μg tetanus toxoid. The vaccine must be reconstituted by adding the entire contents of the syringe to the vial and shaking until the pellet is completely dissolved. May also contain yeast proteins.
Infanrix Penta – GlaxoSmithKline (DTPa-hepB-IPV; diphtheria-tetanusacellular pertussis-hepatitis B-inactivated poliomyelitis vaccine). Each 0.5 mL pre-filled syringe contains 30 IU diphtheria toxoid, 40 IU tetanus toxoid, 25 μg PT, 25 μg FHA, 8 μg PRN, 10 μg recombinant HBsAg, 40 D-antigen units inactivated polioviruses type 1 (Mahoney), 8 D-antigen units type 2 (MEF-1) and 32 D-antigen units type 3 (Saukett) adsorbed onto aluminium hydroxide/phosphate; phenoxyethanol as preservative; traces of formaldehyde, polymyxin and neomycin. May also contain yeast proteins. Other combination vaccines that include hepatitis B
COMVAX – CSL Biotherapies/Merck & Co Inc (Hib (PRP-OMP)-hepatitis B). Each 0.5 mL monodose vial contains 7.5 μg PRP conjugated to 125 μg meningococcal protein, 5 μg hepatitis B surface antigen; 225 μg aluminium hydroxide; 35 μg borax. May contain yeast proteins.
Twinrix Junior (360/10) – GlaxoSmithKline (formaldehyde inactivated hepatitis A virus (HM175 strain) and recombinant hepatitis B vaccine). Each 0.5 mL monodose vial or pre-filled syringe contains 360 ELISA units of HAV antigens, 10 μg recombinant DNA hepatitis B surface antigen protein; 0.225 mg aluminium phosphate/hydroxide; 0.5% w/v phenoxyethanol; traces of formaldehyde and neomycin. May contain yeast proteins.
Twinrix (720/20) – GlaxoSmithKline (formaldehyde inactivated hepatitis A virus (HM175 strain) and recombinant hepatitis B vaccine). Each 1.0 mL monodose vial or syringe contains 720 ELISA units of HAV antigens, 20 μg recombinant DNA hepatitis B surface antigen protein; 0.45 mg aluminium phosphate/hydroxide; 0.5% w/v phenoxyethanol; traces of formaldehyde and neomycin. May contain yeast proteins.
WAVE ~World Association for Vaccine Education
Also is a great resource for ingrediants in the HBV vaccines- it also has the bonus to further click on each ingrediant and learn more about that specific ingrediants adverse reactions. Also has sound scientific sources and articel for further study
http://www.novaccine.com/specific-vaccines/vaccine.asp?v_id=46
AVN ~ Australlian Vaccination Network http://avn.org.au/library/index.php/vaccination-information/hepatitis-b.html
* To be added Hepatitis Vaccine causes Autoimmune and Demyelinating Disease, article from both sides the vaccine bodies whose research concludes no correalation and the science bodies who say otherwise*
BIRTH - Monovalent hepatitis B vaccine
2 MONTHS - Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
4 MONTHS - Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
6 MONTHS- Hepatitis B vaccine given as either monovalent vaccine or in combination with DTPa, at 2, 4 and 6 months
12 MONTHS - Hepatitis B vaccine in combination with Hib (PRO-OMP), at 2, 4 and 12 months.
10-13 YEARS - Hepatitis B vaccine for 10-13 year olds who have not received a primary course
The Australian Immunisation Handbook http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-hepatitisb
Australian vaccination policy
The initial strategy for the control of hepatitis B in Australia commenced in 1988, targeting groups at particular risk of infection for vaccination at birth. In addition to vaccine, hepatitis B immunoglobulin (HBIG) was given if the mother was a hepatitis B carrier. In 1990, universal infant vaccination commenced in the Northern Territory. In 1996, the NHMRC recommended a universal hepatitis B vaccination program for infants and adolescents. The adolescent program commenced in some States and Territories in 1997 and the universal infant program, with the first dose given at birth, began nationally in 2000. The adolescent program will continue until those immunised for hepatitis B in the childhood program reach adolescence.
Recommendations
(i) Infants and young children
A birth dose of thiomersal-free monovalent hepatitis B vaccine, followed by doses given in combination vaccines (such as DTPa-hepB, DTPa-hepB-IPV,
DTPa-hepB-IPV-Hib or Hib (PRP-OMP)-hepB) at 2, 4 and either 6 or 12 months, is recommended for all children.
The rationale for the universal birth dose is not only to prevent vertical transmission from a carrier mother (recognising that there may be errors or delays in maternal testing, reporting, communication or appropriate response), but also to prevent horizontal transmission in the first months of life from a carrier among household or other close contacts.17 The birth dose should be given as soon as the baby is physiologically stable, and preferably within 24 hours of birth. Every effort should be made to administer the vaccine before discharge from the obstetric hospital.
Extensive experience indicates that the birth dose of hepatitis B vaccine is very well tolerated by newborn infants. It does not interfere with either the establishment or maintenance of breastfeeding, and it is not associated with an increased risk of either fever or medical investigation for sepsis in the newborn.18-20 (http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook-hepatitisb#18)
If an infant has missed the birth dose and is aged 8 days or older, a catchup schedule is not required. A primary course of a hepatitis B-containing combination vaccine should be given at 2, 4 and either 6 or 12 months of age (provided the mother is HBsAg negative).
NB. All babies (preterm or term) of carrier mothers must be given a birth dose of hepatitis B vaccine and HBIG.
Vaccines
Engerix-B – GlaxoSmithKline (recombinant DNA hepatitis B vaccine).
Adult formulation – Each 1.0 mL monodose vial contains 20 μg recombinant hepatitis B surface antigen (HBsAg) protein, adsorbed onto 0.5 mg aluminium hydroxide. Paediatric formulation – Each 0.5 mL monodose vial contains 10 μg HBsAg protein, adsorbed onto 0.25 mg aluminium hydroxide. Both formulations contain traces of yeast proteins and thiomersal (<2 μg/mL). Both are available in packs of 10.
H-B-VAX II – CSL Biotherapies/Merck & Co Inc (recombinant DNA hepatitis B vaccine). Adult formulation preservative free – Each 1.0 mL pre-filled syringe or vial contains 10 μg recombinant HBsAg protein, adsorbed onto 0.5 mg aluminium hydroxide. May contain yeast proteins. Paediatric formulation preservative free – Each 0.5 mL pre-filled syringe or vial contains 5 μg recombinant HBsAg protein, adsorbed onto 0.25 mg aluminium hydroxide. May contain yeast proteins. Both are available in packs of 10. Dialysis formulation preservative free – Each 1.0 mL vial contains 40 μg recombinant HBsAg protein, adsorbed onto 0.5 mg aluminium hydroxide. May contain yeast proteins. Available as single pack only.
Combination vaccines that include both DTPa and hepatitis B
Infanrix hexa – GlaxoSmithKline (DTPa-hepB-IPV-Hib; diphtheriatetanus- acellular pertussis-hepatitis B-inactivated poliomyelitis vaccine-Haemophilus influenzae type b (Hib)). The vaccine consists of both a 0.5 mL pre-filled syringe containing 30 IU diphtheria toxoid, 40 IU tetanus toxoid, 25 μg pertussis toxoid (PT), 25 μg filamentous haemagglutinin (FHA), 8 μg pertactin (PRN), 10 μg recombinant HBsAg, 40 D-antigen units inactivated polioviruses type 1 (Mahoney), 8 D-antigen units type 2 (MEF-1) and 32 D-antigen units type 3 (Saukett) adsorbed onto aluminium hydroxide/phosphate; phenoxyethanol as preservative; traces of formaldehyde, polymyxin and neomycin and a vial containing a lyophilised pellet of 10 μg purified Hib capsular polysaccharide (PRP) conjugated to 20–40 μg tetanus toxoid. The vaccine must be reconstituted by adding the entire contents of the syringe to the vial and shaking until the pellet is completely dissolved. May also contain yeast proteins.
Infanrix Penta – GlaxoSmithKline (DTPa-hepB-IPV; diphtheria-tetanusacellular pertussis-hepatitis B-inactivated poliomyelitis vaccine). Each 0.5 mL pre-filled syringe contains 30 IU diphtheria toxoid, 40 IU tetanus toxoid, 25 μg PT, 25 μg FHA, 8 μg PRN, 10 μg recombinant HBsAg, 40 D-antigen units inactivated polioviruses type 1 (Mahoney), 8 D-antigen units type 2 (MEF-1) and 32 D-antigen units type 3 (Saukett) adsorbed onto aluminium hydroxide/phosphate; phenoxyethanol as preservative; traces of formaldehyde, polymyxin and neomycin. May also contain yeast proteins. Other combination vaccines that include hepatitis B
COMVAX – CSL Biotherapies/Merck & Co Inc (Hib (PRP-OMP)-hepatitis B). Each 0.5 mL monodose vial contains 7.5 μg PRP conjugated to 125 μg meningococcal protein, 5 μg hepatitis B surface antigen; 225 μg aluminium hydroxide; 35 μg borax. May contain yeast proteins.
Twinrix Junior (360/10) – GlaxoSmithKline (formaldehyde inactivated hepatitis A virus (HM175 strain) and recombinant hepatitis B vaccine). Each 0.5 mL monodose vial or pre-filled syringe contains 360 ELISA units of HAV antigens, 10 μg recombinant DNA hepatitis B surface antigen protein; 0.225 mg aluminium phosphate/hydroxide; 0.5% w/v phenoxyethanol; traces of formaldehyde and neomycin. May contain yeast proteins.
Twinrix (720/20) – GlaxoSmithKline (formaldehyde inactivated hepatitis A virus (HM175 strain) and recombinant hepatitis B vaccine). Each 1.0 mL monodose vial or syringe contains 720 ELISA units of HAV antigens, 20 μg recombinant DNA hepatitis B surface antigen protein; 0.45 mg aluminium phosphate/hydroxide; 0.5% w/v phenoxyethanol; traces of formaldehyde and neomycin. May contain yeast proteins.
WAVE ~World Association for Vaccine Education
Also is a great resource for ingrediants in the HBV vaccines- it also has the bonus to further click on each ingrediant and learn more about that specific ingrediants adverse reactions. Also has sound scientific sources and articel for further study
http://www.novaccine.com/specific-vaccines/vaccine.asp?v_id=46
AVN ~ Australlian Vaccination Network http://avn.org.au/library/index.php/vaccination-information/hepatitis-b.html
* To be added Hepatitis Vaccine causes Autoimmune and Demyelinating Disease, article from both sides the vaccine bodies whose research concludes no correalation and the science bodies who say otherwise*